Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | HPGD | P15428 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 5/20 | 0.36 |
| ▸ | CASP7 | P55210 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708363 | 0.85 | ALDH1A1 (0.37) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL14257687 | 0.84 | HPGD (0.41) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL4708933 | 0.83 | KDM4E (0.43) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL4709065 | 0.83 | PLAT (0.44) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL14015123 | 0.78 | HPGD (0.37) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL14015115 | 0.77 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL14038873 | 0.77 | L3MBTL1 (0.40) | ALDH1A1HPGDMEN1KMT2AALOX15 | |
| SCHEMBL14038865 | 0.75 | PARP1 (0.38) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL14015116 | 0.75 | ALDH1A1 (0.35) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL4707958 | 0.74 | KDM4E (0.38) | ALDH1A1HPGDKDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1934225-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1511751-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007044410-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2006-05-04 | — | — | US | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | ALDH1A1 482/4885HPGD 1836/4885KDM4E 642/4885 |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CDKN1A, EIF2AK2, DCK | ALDH1A1 1771/4885HPGD 3423/4885KDM4E 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.